HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot, open, prospective, non-randomized study to evaluate the safety and efficacy of switches from etravirine to doravirine, in experienced patients with multiple class resistance including NNRTI resistance. The other ARV medication (protease inhibitor, entry inhibitor and integrase inhibitor) that some patients receive, in addition to the NRTI and NNRTI, will not be changed.

The study will be performed only on two sites

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinique du Quartier Latin
• Collaborator: Merck Frosst Canada Ltd.
• Treatments: Etravirine

Criteria

Inclusion Criteria:

• Adult (18 Y.O. or more) women and men infected with HIV.

• Treated with etravirine and at least 2 others ARV in the other classes: NRTI, PI, INSTI, EI, for at least 12 months.

• Virologically controlled (HIV-1 RNA < 50 copies/mL) since at least 6 months. Blips (HIV-ARN ≥ 50 copies/mL, one time, with return to virologic control at the next visit) are allowed.

• Presence of at least one major NNRTI mutation.

• No limitation on the number of previous regimens.

• HCV and HBV-infected patients are allowed

Exclusion Criteria:

High level of resistance to doravirine according to historical resistance tests.

• Level of resistance to doravirine superior to that of etravirine

• Opportunistic or serious active infection or disease

• Active and untreated malignancy.

• Current psychiatric or neurocognitive condition judged by the Investigator to potentially interfere with study visits and procedures

• Pregnancy.

• Active treatment for hepatitis C is forbidden at entry but will be allowed after 3